High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
DNA abnormalities are used in inclusion criteria of clinical trials for treatments with specific targeted molecules. MYC is one of the most powerful oncogenes and is known to be associated with triple-negative breast cancer (TNBC). Its DNA amplification is often part of the targeted DNA-sequencing p...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2019
|
| 在線閱讀: | https://doi.org/10.3390/ijms21010217 https://www.mdpi.com/1422-0067/21/1/217/pdf?version=1577502639 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|